Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments

被引：0
|
作者：
Andrea Messori
Dario Maratea
Valeria Fadda
Sabrina Trippoli
机构：
[1] ESTAV Toscana Centro,HTA Unit
[2] Regional Health Service,HTA Unit
[3] Area Vasta Centro Toscana,undefined
[4] Regional Health System,undefined
来源：
Lung | 2012年 / 190卷
关键词：
Overall Survival; Elderly Patient; Temporal Trend; Median Overall Survival; Advanced NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：591 / 592
页数：1
相关论文
共 50 条
  • [1] Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments
    Messori, Andrea
    Maratea, Dario
    Fadda, Valeria
    Trippoli, Sabrina
    [J]. LUNG, 2012, 190 (06) : 591 - 592
  • [2] Temporal Trend of Overall Survival in Patients with Advanced Non-small Cell Lung Cancer Given First-Line Cytotoxic Treatments Response
    Qi, Wei-xiang
    Yao, Yang
    [J]. LUNG, 2012, 190 (06) : 592 - 592
  • [3] Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer
    Spence, Michele M.
    Hui, Rita L.
    Chang, Jennifer T.
    Schottinger, Joanne E.
    Millares, Mirta
    Rashid, Nazia
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 159 - 159
  • [4] Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy
    Shen, Jie
    Ye, Yuanqing
    Chang, David W.
    Huang, Maosheng
    Heymach, John V.
    Roth, Jack A.
    Wu, Xifeng
    Zhao, Hua
    [J]. LUNG CANCER, 2017, 114 : 70 - 78
  • [5] Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Popat, Sanjay
    Liu, Stephen V.
    Scheuer, Nicolas
    Gupta, Alind
    Hsu, Grace G.
    Ramagopalan, Sreeram V.
    Griesinger, Frank
    Subbiah, Vivek
    [J]. JAMA NETWORK OPEN, 2022, 5 (05) : E2214046
  • [6] Atezolizumab as first-line therapy for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival
    Marcella, E.
    Susanto, B.
    Chen, S.
    Tandiono, J.
    Tancherla, A.
    Heriyanto, R. S.
    Wijovi, F.
    Kurniawan, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S759
  • [7] Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
    Imai, Hisao
    Kishikawa, Takayuki
    Minemura, Hiroyuki
    Yamada, Yutaka
    Ibe, Tatsuya
    Mori, Keita
    Yamaguchi, Ou
    Mouri, Atsuto
    Hamamoto, Yoichiro
    Kanazawa, Kenya
    Kasai, Takashi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    Minato, Koichi
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    [J]. ONCOLOGY, 2021, 99 (09) : 562 - 570
  • [8] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    [J]. DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [9] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Crawford, Jeffrey
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong Khanh
    Garcia, Jacob
    Barron, Richard
    Lyman, Gary H.
    [J]. SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932
  • [10] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Jeffrey Crawford
    Neelima Denduluri
    Debra Patt
    Xiaolong Jiao
    Phuong Khanh Morrow
    Jacob Garcia
    Richard Barron
    Gary H. Lyman
    [J]. Supportive Care in Cancer, 2020, 28 : 925 - 932
12345